{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T14:14:22Z","timestamp":1754144062916,"version":"3.41.2"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Literature evidence reports that <jats:italic>RNF43<\/jats:italic> (ring finger protein 43) gene mutations could serve as predictive biomarkers of response to certain anti-cancer therapies. To delve deeper into the specific role of <jats:italic>RNF43<\/jats:italic> mutations in lung cancer and their relevance to therapy response, we provide the first report of marked efficacy of the dabrafenib and trametinib therapeutic combination in a patient with microsatellite-stable (MSS) non-small-cell lung cancer (NSCLC) with <jats:italic>BRAF<jats:sup>V600<\/jats:sup><\/jats:italic> and <jats:italic>RNF43<\/jats:italic> mutations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case description<\/jats:title><jats:p>An 85-year-old patient was diagnosed with NSCLC with the presence of MSS, <jats:italic>BRAF<\/jats:italic><jats:sup>V600E<\/jats:sup> and <jats:italic>RNF43<\/jats:italic> mutations. The patient started the combination treatment with dabrafenib and trametinib, soon reporting an overall clinical benefit. A contrast-enhanced cranio\u2013thorax\u2013abdomen CT scan performed after 1 month of therapy reported a sharp reduction in lung cancer and hilo-mediastinal lymphadenomegaly; the central colliquation of the left adrenal metastasis was also reported. After 9 months of therapy, the cranio-thorax-abdomen CT scan with contrast medium confirmed the reduction of the adenocarcinoma, with residual scarring component; the right adrenal lesion was not visible, and the contralateral lesion was stable. At the last follow-up (February 2024), the global clinical condition of the patient was good; she was autonomous, and oxygen therapy was not necessary.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our clinical case represents the first report of marked efficacy of the dabrafenib\u2013trametinib combination reported in an 85-year-old patient diagnosed with NSCLC with the presence of MSS, <jats:italic>BRAF<\/jats:italic><jats:sup>V600E<\/jats:sup> and <jats:italic>RNF43<\/jats:italic> mutations. This supports the hypothesis on the relevance of <jats:italic>RNF43<\/jats:italic> mutations in predicting the clinical benefit of targeted therapies and in modulating the anti-tumor activity of anti-BRAF therapies, suggesting that <jats:italic>RNF43<\/jats:italic> mutations represent a promising biomarker that warrants further validation for its potential to help prioritize therapy combinations in selected lung cancer patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1600457","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T05:24:49Z","timestamp":1752557089000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Enhanced response to dabrafenib plus trametinib in a patient with BRAFV600E lung cancer harboring an RNF43 variant of unknown significance: a case report"],"prefix":"10.3389","volume":"15","author":[{"given":"Ettore","family":"D\u2019Argento","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacopo","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Minucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Cancellieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessio","family":"Stefani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Monaca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Horn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Occhipinti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Troisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Scala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Polidori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"D\u2019Argento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariantonietta","family":"Di Salvatore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Bria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giampaolo","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12041009","article-title":"Personalized medicine: recent progress in cancer therapy","volume":"12","author":"Gambardella","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00004-0","article-title":"Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)","volume":"387","author":"Barlesi","year":"2016","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00077-2","article-title":"Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial","volume":"17","author":"Planchard","year":"2016","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30679-4","article-title":"Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial","volume":"18","author":"Planchard","year":"2017","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.911303","article-title":"Clinical characteristics, co-mutations, and treatment outcomes in advanced non-small-cell lung cancer patients with the BRAF-V600E mutation","volume":"12","author":"Qu","year":"2022","journal-title":"Front Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nature11308","article-title":"Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors","volume":"488","author":"Koo","year":"2012","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2022.105701","article-title":"Whole-exome sequencing analysis of NSCLC reveals the pathogenic missense variants from cancer-associated genes","volume":"148","author":"Kumar","year":"2022","journal-title":"Comput Biol Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26678","article-title":"Genetic interaction analysis among oncogenesis-related genes revealed novel genes and networks in lung cancer development","volume":"10","author":"Li","year":"2019","journal-title":"Oncotarget"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01976-z","article-title":"RNF43 mutations predict response to anti-BRAF\/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer","volume":"28","author":"Elez","year":"2022","journal-title":"Nat Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1186\/s40001-023-01383-1","article-title":"Pan-cancer analysis identifies RNF43 as a prognostic, therapeutic and immunological biomarker","volume":"28","author":"Xu","year":"2023","journal-title":"Eur J Med Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202304820","article-title":"RNF43 inactivation enhances the B-RAF\/MEK signaling and creates a combinatory therapeutic target in cancer cells","volume":"11","author":"Hsu","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ccell.2017.12.004","article-title":"Clinical sequencing defines the genomic landscape of metastatic colorectal cancer","volume":"33","author":"Yaeger","year":"2018","journal-title":"Cancer Cell"},{"key":"B14","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1038\/s41467-020-18257-3","article-title":"A phospho-switch controls RNF43-mediated degradation of Wnt receptors to suppress tumorigenesis","volume":"11","author":"Tsukiyama","year":"2020","journal-title":"Nat Commun"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.65759","article-title":"RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy","volume":"10","author":"Radaszkiewicz","year":"2021","journal-title":"Elife"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt356","article-title":"Wnt signaling pathway in non-small cell lung cancer","volume":"106","author":"Stewart","year":"2014","journal-title":"J Natl Cancer Inst"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1600457\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T05:24:49Z","timestamp":1752557089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1600457\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":16,"alternative-id":["10.3389\/fonc.2025.1600457"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1600457","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"article-number":"1600457"}}